| Document |
Document Title |
|
WO/2022/174451A1 |
A multi-domain fusion protein having anti-cancer activity, and a preparation method therefor and the use thereof. The fusion protein comprises an anti-PD-L1 single-domain antibody fragment, an antagonistic VEGF fragment, and a TGF-β bin...
|
|
WO/2022/177466A1 |
Group of invention relates to biotechnology, immunology and virology. Described is the use of an agent containing expression vector based on strain human adenovirus serotype 26 or human adenovirus serotype 5, in which E1 and E3 regions a...
|
|
WO/2022/171192A1 |
The present application provides antibodies comprising an antigen-binding fragment of an anti-CD3 antibody having tailor-made affinity to CD3 in low to medium range. In some embodiments, the antibody further comprises an antigen-binding ...
|
|
WO/2022/171068A1 |
Provided are engineered cells (such as stem cells or T cells) that have a surface molecule comprising a membrane-tethered binding moiety that binds to a T cell surface antigen (such as CCR5, CD4 or CXCR4) or a HIV antigen, or a membrane ...
|
|
WO/2022/173424A1 |
A fusion protein, comprising a variant angiotensin converting enzyme 2 (ACE2) domain covalently fused to a Fc domain. The variant ACE2 domain has a N-terminal deletion, a C-terminal deletion, or both, relative to a full-length wildtype A...
|
|
WO/2022/171852A1 |
The invention relates to variants of OB-fold proteins, in particular of the Sac7d family that bind to human and mouse serum albumin and that can be used to increase serum half-life of elements associated therewith.
|
|
WO/2022/173377A1 |
The present invention relates to methods that employ enzymes having Asx-specific ligase and cyclase activity, namely butelase-1, VyPAL2 and OaAEPI b, as a means for engineering novel (poly) peptide theranostics. The differential substrat...
|
|
WO/2022/168861A1 |
The present invention provides a polypeptide having an amino acid sequence capable of binding to NRP1 and an amino acid sequence capable of inducing apoptosis.
|
|
WO/2022/166977A1 |
Provided are an anti-human IL-36R monoclonal antibody and an application thereof. A murine anti-human IL-36R monoclonal antibody is prepared by a hybridoma technology; the murine anti-human IL-36R antibody is screened to obtain an antibo...
|
|
WO/2022/166720A1 |
Provided is a fusion protein, comprising a protein having a hydrophobic region, a peptide linker, a protein fusion receptor. The peptide linker links the protein having a hydrophobic region to the protein fusion receptor. The protein fus...
|
|
WO/2022/170179A1 |
The present invention features methods and compositions directed towards a recombinant polypeptide biopolymer composition that are effective as nano springs. The composition of the present invention comprises both a streptavidin polypept...
|
|
WO/2022/165608A1 |
Disclosed is a method of treating a neurodegenerative disease such as Parkinson's disease, diffuse Lewy body disease, transitional Lewy body dementia, and multiple system atrophy in a subject. The method comprises administering to the su...
|
|
WO/2022/166365A1 |
Provided is a chimeric antigen receptor, comprising an antigen binding region, a transmembrane domain and an intracellular signaling region. The antigen binding region comprises an antibody specifically targeting CD7, and the intracellul...
|
|
WO/2022/166806A1 |
Provided is a novel CD271-based antigenic epitope peptide. The epitope peptide is: (1) located in SEQ ID NO.1; or (2) located in an amino acid sequence having at least 80% identity with the sequence SEQ ID NO.1 in (1), SEQ ID NO.1 contai...
|
|
WO/2022/166895A1 |
Provided are a novel Cas effector protein that can exhibit a nuclease activity in cells and outside of cells and the use thereof.
|
|
WO/2022/166831A1 |
The present invention relates to a recombinant fusion protein and a nano-assembly, and preparation methods therefor and the use thereof. The nano-assembly is formed by means of combining at least one recombinant fusion protein and a hydr...
|
|
WO/2022/166665A1 |
The present application provides an endogenous chimeric antigen receptor (ECAR). An antigen-binding domain in the endogenous chimeric antigen receptor is an endogenous protein molecule. The engineered immune cells in the present inventio...
|
|
WO/2022/164222A2 |
Provided is a pharmaceutical composition for prevention or treatment of pulmonary diseases, the pharmaceutical composition comprising a GIP derivative, a pharmaceutically acceptable salt thereof, a solvate thereof, or a long-acting conju...
|
|
WO/2022/161472A1 |
The present disclosure provides single domain antibodies that bind to SARS-CoV-2 S1, and fusion proteins comprising same. Pharmaceutical compositions, kits and methods of preventing or treating a disease or disorder such as a respiratory...
|
|
WO/2022/162623A1 |
The present disclosure relates to systems, compositions and methods for modifying target nucleic acid sequences.
|
|
WO/2022/161409A1 |
The present invention provides a bispecific CS1-BCMA CAR-T cell and an application thereof. Specifically, the present invention provides a bispecific CAR, which comprises CS1 scFv and BCMA scFv, and a 4-1BB co-stimulatory domain and a CD...
|
|
WO/2022/162533A1 |
The present invention relates, in general, to polypeptides capable of neutralizing SARS-CoV-2 and providing ACE2 enzymatic activity, and uses of these polypeptides for treating disorders related coronaviral infections (COVID-19) and the ...
|
|
WO/2022/160601A1 |
Disclosed are a gallium 68 labeled affibody protein PET imaging agent and a use; the imaging agent comprises 68Ga-Z-tri; the 68Ga-Z-tri is obtained by labeling an affibody protein with gallium 68; the affibody protein comprises a PDGFR-Î...
|
|
WO/2022/163647A1 |
Provided is a vaccine that can be administered orally against coronavirus infection. A vaccine that can be administered orally against coronavirus infection can be provided by transformed bifidobacteria designed so as to present some or ...
|
|
WO/2022/160057A1 |
In aspects, a fusion protein comprises a nanocage monomer or a subunit thereof linked to an Fc monomer, wherein a plurality of the fusion proteins are capable of self-assembling to form a nanocage comprising one or more Fc dimers. In asp...
|
|
WO/2022/162704A1 |
The present invention discloses a therapeutic composition comprising fusion protein with reduced heterogeneity in the glycosylation profile of the protein and methods thereof. More particularly the invention provides the composition with...
|
|
WO/2022/162191A2 |
This invention describes the formation and use of collections of pMHC Multiplexers. A pMHC Multiplexer is a spatially confined composition of at least two molecules, an encoding molecule and a peptide (and/or protein) that is encoded by ...
|
|
WO/2022/156189A1 |
The use of a polypeptide compound in the preparation of a drug for the prevention or treatment of inflammatory bowel disease and intestinal fibrosis related thereto. The polypeptide compound contains a parent peptide as represented by th...
|
|
WO/2022/159741A1 |
The present invention relates to nucleases or nucleic acids encoding the nucleases, RNA guides or nucleic acids encoding the RNA guides, processes for characterizing the nucleases and/or RNA guides, compositions comprising the nucleases ...
|
|
WO/2022/157714A1 |
The present disclosure relates to a single domain antibody that specifically binds to the epitope in the catalytic domain of carbonic anhydrase IX (CA-IX). The single domain antibody has a dissociation constant (KD) of 1 x 10-7 or lower ...
|
|
WO/2022/159620A1 |
Provided herein are methods and compositions relating to adenosine A2A receptor libraries having nucleic acids encoding for a scaffold comprising an adenosine A2A binding domain. adenosine A2A receptor libraries described herein encode f...
|
|
WO/2022/156531A1 |
Disclosed are a dynein binding peptide capable of permeating through a biological barrier, and the use thereof. The polypeptide provided by the present invention is a polypeptide A or a polypeptide B, wherein the polypeptide A is sequent...
|
|
WO/2022/159730A1 |
A method of treating lung inflammation caused by a viral infection is disclosed. The method of treatment can include topoisomerase I inhibitors and pharmaceutical compositions comprising topoisomerase I inhibitors, which can be administe...
|
|
WO/2022/156786A1 |
Provided is a chimeric antigen receptor-engineered NK cell, the chimeric antigen receptor comprising: an extracellular target molecule binding domain, a transmembrane region domain, and an intracellular signal transduction domain. The tr...
|
|
WO/2022/158505A1 |
This material for virus concentration comprises: a fiber aggregate that has fibers; and an antibody that is against a target virus and is supported on the surface of the fibers. The median fiber diameter of the fibers is less than 20 μm...
|
|
WO/2022/155706A1 |
The present invention relates to chimeric and fusion proteins and their compositions, and the use of such proteins and compositions in the prevention and/or treatment diseases or conditions requiring plasminogen supplementation. In one a...
|
|
WO/2022/159433A1 |
This invention provides compositions and methods to treat, prevent, and diagnose viral infections. The methods provided herein involve administering one or more polypeptides of the invention to a subject in need thereof. The viral infect...
|
|
WO/2022/159395A1 |
Disclosed herein are small molecule GIP/GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2022/153307A1 |
Type I membrane proteins heterodimers are provided. Accordingly, there is provided a heterodimer comprising two polypeptides selected from the group consisting of SIRP alpha, PD1, TIGIT, LILRB2 and SIGLEC10, wherein each of the two polyp...
|
|
WO/2022/154632A1 |
Disclosed is a switching peptide that can be applied to an electrochemical immunoassay. The switching peptide includes: a peptide compound capable of binding reversibly to a binding antibody; and a chemical marker grafted to the peptide ...
|
|
WO/2022/150899A1 |
The present invention relates to the field of diagnostic medicine, vaccinology and biotechnology. More specifically, the present invention relates to a chimeric protein for use in diagnosing visceral leishmaniasis in humans and dogs, inc...
|
|
WO/2022/152186A1 |
Provided is a fully human single-domain tandem chimeric antigen receptor (CAR) capable of specifically binding to a CD5 protein, which CAR contains a CD5 binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellul...
|
|
WO/2022/151958A1 |
Provided are a human CD276-targeting monoclonal antibody and an application thereof. Specifically, provided are a CD276-targeting antibody, which has a high affinity and a high specificity for human CD276. Further provided are a pharmace...
|
|
WO/2022/154127A1 |
The present invention provides a desired antibody or antibody composition by modifying a thiol group chemically introduced into an antibody. More specifically, the present invention provides an antibody composition, etc., having desired ...
|
|
WO/2022/152308A1 |
Provided herein is an engineered dimeric antibody comprising in each monomer a Fab domain specifically binding to a Trop2 antigen operably linked to an engineered hinge region, wherein the engineered hinge region is composed of a portion...
|
|
WO/2022/155503A1 |
Provided herein are multispecific antigen binding proteins that selectively bind a particular KKLC-1 (CT-83) shared antigen and CD3, as well as related methods, kits, and compositions. Included herein are multispecific antigen binding pr...
|
|
WO/2022/151959A1 |
The present invention provides a CAR-T cell targeting B7-H3 and an application thereof in the treatment of acute myeloid leukemia (AML). Specifically, the present invention provides a CAR-T cell targeting B7-H3, which comprises an scFv w...
|
|
WO/2022/153698A1 |
The purpose of the present invention is to provide a chimeric target factor receptor which can activate an antigen presenting cell, e.g., a dendritic cell, in a target-factor-specific manner. A chimeric target factor receptor is provided...
|
|
WO/2022/151746A1 |
A fusion enzyme and the use thereof in a paper-based biosensor. A GDH-linker-CBM fusion enzyme constructed by a flavin adenine dinucleotide (FAD)-dependent glucose dehydrogenase (GDH) gene and a carbohydrate binding module (CBM) gene, wh...
|
|
WO/2022/154547A1 |
Disclosed is a switching peptide applicable to a multiplex immunoassay method. The switching peptide comprises: a peptide compound capable of reversibly binding to a binding antibody; and a mass label substance bound to the peptide compo...
|
